Invalidity dossier
US 9127049
Human cytomegalovirus neutralizing antibodies and use thereof
Current assignee: Institute for Research in Biomedicine
Added 9/21/2026, 10:41:19 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US9127049B2
Title: Human cytomegalovirus neutralizing antibodies and use thereof
Patent number / application: US9127049B2; application US14/138,531; publication US20140205615A1.
Inventors: Antonio Lanzavecchia and Annalisa Macagno.
Assignee: Institute for Research in Biomedicine (IRB), listed as both original and current assignee. An assignment recorded 2014-04-09 names Lanzavecchia and Macagno as assignors.
Key dates: Priority date 2008-07-16; filing date 2013-12-23; publication date 2015-09-08; anticipated expiration 2029-07-15. Legal status is listed as "Expired – Fee Related."
Purpose and plain-language scope: The invention concerns human antibodies that neutralize human cytomegalovirus (HCMV), and uses of those antibodies. The classifications place it in immunoglobulin technology (C07K16/00, C07K16/089 for cytomegalovirus), medicinal preparations containing antibodies (A61K39/395, A61K39/42), and antiviral/anti-herpes activity (A61P31/20, A61P31/22). Suggested classification tags indicate human-origin antibodies, binding to a defined epitope (linear under 20 residues or a conformational epitope), glycosylation features, and antibody fragments such as Fab, Fab', F(ab')2, Fv, and scFv. Prior-art keywords listed are antibody, SEQ, antibodies, HCMV, and epitope, implying sequence-listing content.
The excerpt also notes that the family has litigation, with a link to a third-party litigation dataset, and lists numerous later applications claiming priority to or from related filings (e.g., US14/815,162; US14/973,409; US15/156,786; US15/284,799; US15/637,513; US15/716,818; US16/025,296; US16/527,836; US17/011,934).
What the excerpt does not establish: It does not include the claims, written description, examples, or sequence listings, so the actual antibody sequences, epitopes, dosages, and claimed subject matter cannot be stated. It does not establish validity, enforceability, the outcome or parties of any litigation, current ownership, or the content of cited prior art. Classification entries and the litigation link are metadata, not legal conclusions.
Source: https://patents.google.com/patent/[US9127049](/patent/US9127049)/en
Generated 10/1/2026, 10:01:19 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 9127049. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.